Heterogeneity of weight gain after initiation of Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis

BACKGROUND: The introduction of the novel therapy, Elexacaftor/Tezacaftor/Ivacaftor (ETI) has been effective in improving weight gain in both clinical trials and real-world studies. However, the magnitude of this effect appears to be heterogeneous across patient subgroups. This study aims to identif...

Descripción completa

Detalles Bibliográficos
Autores principales: Gramegna, Andrea, Majo, Fabio, Alicandro, Gianfranco, Leonardi, Gloria, Cristiani, Luca, Amati, Francesco, Contarini, Martina, Aliberti, Stefano, Fiocchi, Alessandro Giovanni, Blasi, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276411/
https://www.ncbi.nlm.nih.gov/pubmed/37330504
http://dx.doi.org/10.1186/s12931-023-02451-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276411/
https://www.ncbi.nlm.nih.gov/pubmed/37330504
http://dx.doi.org/10.1186/s12931-023-02451-0

Ejemplares similares